

Release, November 30,2020

Title: Registered shares BB Biotech AG of CHF 0.20 par value each

Security: 3,838,999 / 2,765,979

ISIN: CH0038389992 / CH0027659793

Repurchase of own shares for the purpose of capital reduction / change of mandated bank and delegation agreement

BB Biotech AG has decided to entrust another bank with the continuation of the buyback program for the remaining buyback volume.

As of 1 December 2020, Zürcher Kantonalbank will, on behalf of BB Biotech AG as sole stock exchange member, quote bid prices for registered shares of BB Biotech AG on the separate trading line on the SIX Swiss Exchange. Accordingly, a delegation agreement has been concluded between BB Biotech AG and Zürcher Kantonalbank pursuant to art. 124 para. 2 lit. a and para. 3 FMIO, according to which Zürcher Kantonalbank will conduct independent buybacks from 1 December 2020, subject to compliance with defined parameters. However, BB Biotech AG has the right to terminate this delegation agreement at any time without giving reasons or to amend it pursuant to art. 124 para. 3 FMIO.

In all other respects, the provisions of the Repurchase Offer dated 11 April 2019 remain unchanged.

Security / ISIN / Ticker

Registered share BB Biotech AG: 3 838 999 / CH0038389992 / BION

Registered share BB Biotech AG (share buyback second line): 2 765 979 / CH0027659793 / BIOEE

Date: 30.11.2020

Bank: Zürcher Kantonalbank

Person: DominicENZler

Phone: 044 292 20 11

E-mail: dominic.enzler@zkb.ch

For further information:

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland,
Tanja Chicherio, +41 44 267 67 00, tch@bellevue.ch

www.bbbiotech.com

Company profile

BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in Switzerland, Germany and Italy. Since 1993, the company has invested in innovative drug development companies that are mainly located in the US and Western Europe. BB Biotech is one of the leading investors in this sector. BB Biotech builds on the long-standing experience of its distinguished Board of Directors and on the fundamental analysis of the experienced Investment Management Team of Bellevue Asset Management AG when making its investment decisions.

Disclaimer

This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.